186 related articles for article (PubMed ID: 20526094)
1. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos D; Tan DS; Jones RL; Judson IR
Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
Mitsiades CS; Mitsiades N
Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
[TBL] [Abstract][Full Text] [Related]
7. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors.
Pandini G; Wurch T; Akla B; Corvaia N; Belfiore A; Goetsch L
Eur J Cancer; 2007 May; 43(8):1318-27. PubMed ID: 17451939
[TBL] [Abstract][Full Text] [Related]
8. Targeting IGF-1R in the treatment of sarcomas: past, present and future.
Kim SY; Wan X; Helman LJ
Bull Cancer; 2009; 96(7):E52-60. PubMed ID: 19617179
[TBL] [Abstract][Full Text] [Related]
9. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
10. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
Hendrickson AW; Haluska P
Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
[TBL] [Abstract][Full Text] [Related]
11. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor system and sarcomas.
Rikhof B; de Jong S; Suurmeijer AJ; Meijer C; van der Graaf WT
J Pathol; 2009 Mar; 217(4):469-82. PubMed ID: 19148905
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
14. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.
Zha J; Lackner MR
Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853
[TBL] [Abstract][Full Text] [Related]
15. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
17. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
18. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations.
Olmos D; Martins AS; Jones RL; Alam S; Scurr M; Judson IR
Sarcoma; 2011; 2011():402508. PubMed ID: 21647361
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
Ryan PD; Goss PE
Oncologist; 2008 Jan; 13(1):16-24. PubMed ID: 18245009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
